Earl Brien
Orthopaedic Surgery · Los Angeles, CANPI 1518024702
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,066 of the $47,555 with a category attached, or 90.6%. UOC USA Inc accounts for 93.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $17,679 and has fallen 70.4% since, to $5,240 in 2025.
Across 58 payments — averaging $819.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UOC USA Inc$44K
- Daiichi Sankyo Inc.$2K
- Stryker$339
- Carbofix Orthopedics Inc$253
- Convatec Inc.$204
- Illuminoss Medical, Inc.$169
- plus $266 from 4 others
What the payments were for
- Consulting fees$43,06691%
- Travel & lodging$1,7444%
- Food & beverage$2,7446%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UOC USA Inc | 33 | $44,477 |
| Daiichi Sankyo Inc. | 11 | $1,846 |
| Stryker | 3 | $339 |
| Carbofix Orthopedics Inc | 3 | $253 |
| Convatec Inc. | 3 | $204 |
| Illuminoss Medical, Inc. | 1 | $169 |
| Acumed LLC | 1 | $110 |
| Biocomposites Inc | 1 | $95 |
| Leica Microsystems Inc. | 1 | $40 |
| Checkpoint Surgical, Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- U-Star II$20,632
- USTAR II$14,092
- N/A$2,948
- U-Motion II$2,948
- U-Motion II, Conformity, U2, AiO, U-Star, UTS, UTF, PSA$1,965
- Turalio$1,586
- Constrained Liner$1,310
- MAKO$273
- Photodynamic Bone Stabilization Procedure Pack$169
- U2, AiO, Disposable Trials, Conformity, U-MotionII, U-Star$127
- U-Star II, Constrained Liner$115
- Vivorte Trabexus$110
- Vivorte Fortera$110
How this compares
$47,555 in reported general payments places this provider in the 85th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 21 | $73 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Los Angeles
- Kelly VinceLos Angeles$9.6M
- Jay LiebermanLos Angeles$4.8M
- Thomas SchmalzriedLos Angeles$4M
- David SkaggsLos Angeles$2.6M
- David ThordarsonLos Angeles$2.5M
- Edward McPhersonLos Angeles$1.2M
- Daniel AllisonLos Angeles$1.1M
- Justin SalimanLos Angeles$912K
- Charles MoonLos Angeles$760K
- Andrew SpitzerLos Angeles$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.